article thumbnail

The MEK effect on cancer — a slow and steady approach to drug resistance

PharmaVoice

This slow and steady concept gained more validation in June when the company announced early but promising data from a phase 2 trial of its MEK inhibitor atebimetinib combined with chemotherapy, which showed a six-month 94% overall survival in pancreatic cancer.

Immunity 130
article thumbnail

Beta Drugs raises Rs 117 cr from HealthQuad and others

Express Pharma

Beta Drugs offers a broad product portfolio across major oncology segments, including chemotherapy, targeted, hormonal and supportive therapy. The company was also honoured with the Forbes “Best Under a Billion” award in 2024.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

With ADCs on the rise, drugmakers embrace a new oncology pillar

PharmaVoice

At ASCO, one of the most talked-about studies was a late-stage trial in which the treatment outperformed chemotherapy as a first-line drug. As we move earlier, almost all of our trials will be in combination with different [immuno-oncology] drugs and … even chemotherapy drugs,” Keller said. “As

article thumbnail

Insights From ASCO 2025 Guide Pharmacy Practice in Solid Tumors and Hematologic Cancers

Pharmacy Times

14,15 Lung Cancer Tarlatamab Significantly Improves Survival in Patients With Small Cell Lung Cancer Post Progression Tarlatamab has shown promising efficacy in relapsed SCLC based on the initial single-arm trial findings, leading to an FDA approval in 2024, but challenges with administration have limited its widespread adoption.

article thumbnail

New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma

Pharmacy Times

Because of its aggressive nature, MCL is typically treated with combination chemotherapy at diagnosis. 5 Phase 3 ECHO Trial: A New Frontline Option The approval was supported by data from the phase 3 ECHO trial (NCT02972840), presented at the 2024 European Hematology Association Hybrid Congress. June 21, 2024. Hemasphere.

article thumbnail

Study Reveals Gaps in GINA Guideline Adherence for Asthma Treatment

Pharmacy Times

2024 Global Strategy for Asthma Mnagement and Prevention Guidelines. Related Videos Related Content Advertisement June 9th 2025 Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC Luke Halpern, Assistant Editor June 3rd 2025 S2. Charlotte, NC; June 9, 2025. Accessed June 9, 2025.

article thumbnail

Evaluation of a Pharmacy-Delivered Oncofertility Intervention

Pharmacy Times

Approximately 40% to 80% of patients with cancer who are assigned female at birth face possible infertility as a result of their cancer treatments, such as chemotherapy, radiation, and surgery. An additional 15% to 30% of cancer survivors who are assigned male at birth also face infertility as a result of chemotherapy.